Alaunos Therapeutics

Alaunos Therapeutics is developing therapeutic treatments for obesity and metabolic health. It aims to develop an oral small molecule to treat obesity and other metabolic disorders, with the potential for a differentiated profile relative to currently available therapies. The company states that its product candidates are distinct in that they do not rely on hormonal manipulation, which it notes is common with many obesity treatments. The program seeks to develop an oral therapeutic with certain advantages and an improved tolerability profile. The company has identified a lead compound for continued preclinical evaluation and has completed two non-GLP pharmacology studies establishing proof-of-concept in the diet induced obesity (DIO) mouse model. It continues to conduct preclinical activities intended to inform the planning of investigational new drug (IND)-enabling studies.

Alaunos Therapeutics is developing therapeutic treatments for obesity and metabolic health. The company aims to develop an oral small molecule to treat obesity and other metabolic disorders, with the potential for a differentiated profile relative to currently available therapies. It states that its product candidates are distinct in that they do not rely on hormonal manipulation, which it notes is common with many obesity treatments. The program seeks to develop an oral therapeutic with certain advantages and an improved tolerability profile. The company has identified a lead compound for continued preclinical evaluation. It completed two non-GLP pharmacology studies establishing proof-of-concept in the diet induced obesity (DIO) mouse model; observations were encouraging and consistent with statistically significant dose-related reductions in body weight, with data indicating statistically significant improvements in body composition, specifically percentage fat and relative preservation of percentage lean, alongside favorable changes in metabolic parameters. The company continues to conduct preclinical activities intended to inform the planning of investigational new drug (IND)-enabling studies.

Developing an oral, non-incretin small molecule for obesity and metabolic health, with candidates that do not rely on hormonal manipulation.

1. 1Alaunos – Oral, non-incretin small molecules for Obesityalaunos.com
2. 2Alaunos Therapeuticswikidata.org